Renaissance Technologies LLC Purchases 17,700 Shares of DaVita Inc. $DVA

Renaissance Technologies LLC grew its holdings in DaVita Inc. (NYSE:DVA) by 10.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 189,200 shares of the company’s stock after acquiring an additional 17,700 shares during the quarter. Renaissance Technologies LLC’s holdings in DaVita were worth $29,078,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership grew its stake in shares of DaVita by 114.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,190,000 shares of the company’s stock worth $135,196,000 after acquiring an additional 636,191 shares in the last quarter. Norges Bank acquired a new stake in shares of DaVita during the 4th quarter worth about $49,164,000. Corient Private Wealth LLC increased its stake in shares of DaVita by 1,493.1% during the fourth quarter. Corient Private Wealth LLC now owns 358,299 shares of the company’s stock worth $40,706,000 after purchasing an additional 335,809 shares during the period. Man Group plc raised its stake in DaVita by 1,608.6% in the 2nd quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after purchasing an additional 269,081 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its stake in DaVita by 2,905.7% during the 3rd quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock worth $30,324,000 after acquiring an additional 220,628 shares during the period. Institutional investors own 90.12% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on DVA. UBS Group upped their target price on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Barclays increased their price objective on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 8th. Zacks Research lowered DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Finally, Truist Financial lifted their target price on shares of DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. Two research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $216.50.

Insider Buying and Selling

In other news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.90% of the stock is owned by corporate insiders.

DaVita Price Performance

DaVita stock opened at $239.82 on Wednesday. The business has a fifty day moving average price of $215.24 and a 200-day moving average price of $170.86. DaVita Inc. has a one year low of $101.00 and a one year high of $241.73. The firm has a market capitalization of $15.40 billion, a P/E ratio of 22.25, a PEG ratio of 0.77 and a beta of 0.88.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. DaVita’s quarterly revenue was up 6.0% on a year-over-year basis. During the same period last year, the firm posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Sell-side analysts expect that DaVita Inc. will post 15.07 earnings per share for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.